M-M-R II vaccine
Sponsors
Sanofi Pasteur, a Sanofi Company, Sanofi
Conditions
Pneumococcal Immunization
Phase 3
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruitingNCT06736041
Start: 2024-12-18End: 2027-05-17Updated: 2026-02-18
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruitingNCT06824181
Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
RecruitingNCT06824194
Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03